profit from every $100 of sales.
$0$100
UFP Technologies
$314.05+0.00% today
+27.9% in 1 year
1-year low $185.451-year high $334.84
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $35.61 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What UFP Technologies sold, what it kept, and what it did with the cash.
Sales went from $354 million in 2022 to $603 million in 2025, with $68.3 million of profit last year.
SalesProfit
UFP Technologies vs. similar companies
UFP Technologies grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| UFP Technologies | 35.6× · Expensive | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads UFP Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 354 | 400 | 504 | 603 | |
| 90 | 112 | 147 | 170 | |
| 44 | 61 | 84 | 93 | |
| 67 | 69 | 96 | 111 | |
| 42 | 45 | 59 | 68 | |
| 5.45 | 5.83 | 7.58 | 8.75 | |
| 25.5% | 28.1% | 29.1% | 28.3% | |
| 12.6% | 15.3% | 16.7% | 15.4% | |
| 11.8% | 11.2% | 11.7% | 11.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 378 | 404 | 629 | 655 |
| Cash | 4 | 5 | 13 | 20 |
| Total debt | 68 | 46 | 206 | 154 |
| Total liabilities | 141 | 118 | 286 | 231 |
| 238 | 286 | 343 | 424 | |
| 8 | 8 | 8 | 8 | |
| 14.3% | 13.7% | 11.7% | 12.6% | |
| 17.6% | 15.7% | 17.2% | 16.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18 | 41 | 67 | 92 | |
| 14 | 10 | 10 | 13 | |
| 4 | 31 | 57 | 79 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 5 | 7 | 9 |
Valuation
- 35.6×
- 33.1×
- 2.08
- 3.9×
- 4.0×
- 30.8×
- 23.0×
- 3.2%
- 2.8%
- 0.0%
Profitability
- 28.3%
- 15.4%
- 11.3%
- 19.1%
- 12.3%
- 11.1%
- 16.6%
- 10.2%
- 15.5%
- –
Growth
- +19.4%
- +17.1%
- +38.7%
- –
- +0.6%
Financial health
- 1.2×
- 0.36
- 23.1%
- 10.6×
- 2.91
- 1.69
- 0.90
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 958
Top 33%of 889
Bottom 35%of 601
Top 29%of 890
Top 34%of 987
What analysts expect
- Average price target
- $298.00
- Range
- $252.00 – $344.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | 2.48 | 2.18 | +13.8% |
| Feb 24, 2026 | 2.44 | 2.26 | +8.0% |
| Nov 3, 2025 | 2.39 | 2.22 | +7.7% |
| Aug 4, 2025 | 2.50 | 2.29 | +9.2% |
| May 6, 2025 | 2.47 | 2.05 | +20.5% |
| Feb 25, 2025 | 2.46 | 1.98 | +24.2% |
| Nov 5, 2024 | 2.11 | 1.81 | +16.6% |
| Jul 31, 2024 | 1.75 | 1.53 | +14.4% |
News
Lumen Technologies (LUMN) Could Be 47% Undervalued On Fresh Third Quarter ResultsYahoo Finance · Nov 8, 2026bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1MSeeking Alpha · Nov 6, 2026The Biggest Takeaway From Palantir Technologies’ Latest Quarterly Report Is a Potential Warning Sign Investors Shouldn’t MissYahoo Finance · Nov 6, 2026Ormat Technologies declares $0.12 dividendSeeking Alpha · Nov 5, 2026Better Nuclear Energy Stock to Buy After the Sell-Off: Oklo vs. BWX TechnologiesYahoo Finance · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
47No pass
Philip Fisher
54No pass
Peter Lynch
57No pass
Joel Greenblatt
14No pass
Charlie Munger
46No pass
Terry Smith
47No pass
Questions about UFP Technologies
Is UFP Technologies a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the UFP Technologies AI analysis
What does UFP Technologies do?
UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. It is in Medical - Devices.
Does UFP Technologies pay a dividend?
No. UFP Technologies does not pay a dividend at the moment.
Is UFP Technologies stock halal?
Yes. UFP Technologies passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has UFP Technologies stock done over the past year?
Up 27.9% over the past twelve months, to $314.05. It traded between $185.45 and $334.84 and is 6.2% below its high.
Who are UFP Technologies's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with UFP Technologies's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.